Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2018
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M Aapro, Y Beguin, C Bokemeyer, et al.
Leukemia
|
August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori, S Suciu, R Stasi, et al.
Leukemia
|
September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia Research
|
January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction
F Ramos, S Thépot, L Pleyer, et al.
Leukemia
|
May 1, 1996
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group
M Unterhalt, R Herrmann, M Tiemann, et al.
Blood
|
November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
U Platzbecker, P Fenaux, L Adès, et al.
Leukemia
|
May 27, 2017
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
G Garcia-Manero, M A Sekeres, M Egyed, et al.
Journal of Internal Medicine
|
December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
H K G Garelius, W T Johnston, A G Smith, et al.
Leukemia Research
|
June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes
G Caocci, M T Voso, E Angelucci, et al.
Leukemia
|
June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?
J Schanz, H Tüchler, F Solé, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2018
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M Aapro, Y Beguin, C Bokemeyer, et al.
Leukemia
|
August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori, S Suciu, R Stasi, et al.
Leukemia
|
September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia Research
|
January 21, 2015
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction
F Ramos, S Thépot, L Pleyer, et al.
Leukemia
|
May 1, 1996
Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group
M Unterhalt, R Herrmann, M Tiemann, et al.
Blood
|
November 9, 2018
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
U Platzbecker, P Fenaux, L Adès, et al.
Leukemia
|
May 27, 2017
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
G Garcia-Manero, M A Sekeres, M Egyed, et al.
Journal of Internal Medicine
|
December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
H K G Garelius, W T Johnston, A G Smith, et al.
Leukemia Research
|
June 30, 2015
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes
G Caocci, M T Voso, E Angelucci, et al.
Leukemia
|
June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?
J Schanz, H Tüchler, F Solé, et al.
Page
of 6